Immunobiology and Intraperitoneal Immunobiologics in Ovarian Cancer

摘要: Advances continue to be made in tumor immunology and strategies integrate the growing number of bioimmunotherapeutic molecules into treatment ovarian cancer, as well other malignancies. Extensive studies have provided support for antigen-driven T-cell activation vivo. The known antigen epitopes is expanding, although advances this area remain behind that melanoma. Evidence suggests environment contributing a state vivo immunosuppression; however, vitro experiments laboratory correlative also show immune suppressor activity might reversible. These findings could lead new approaches, such use antibodies or cytokines overcome immunosuppressive effects, addition more established surgical chemotherapeutic debulking.